- Home
- IVR vs TCRX Comparison
IVR vs TCRX Comparison
Compare IVR & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVR
- TCRX
- Stock Information
- Founded
- IVR 2008
- TCRX 2018
- Country
- IVR United States
- TCRX United States
- Employees
- IVR N/A
- TCRX N/A
- Industry
- IVR Real Estate Investment Trusts
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- IVR Real Estate
- TCRX Health Care
- Exchange
- IVR Nasdaq
- TCRX Nasdaq
- Market Cap
- IVR 472.5M
- TCRX 285.5M
- IPO Year
- IVR 2009
- TCRX 2021
- Fundamental
- Price
- IVR $8.74
- TCRX $5.26
- Analyst Decision
- IVR Buy
- TCRX Strong Buy
- Analyst Count
- IVR 4
- TCRX 5
- Target Price
- IVR $8.00
- TCRX $11.40
- AVG Volume (30 Days)
- IVR 1.5M
- TCRX 208.4K
- Earning Date
- IVR 11-04-2024
- TCRX 11-07-2024
- Dividend Yield
- IVR 18.30%
- TCRX N/A
- EPS Growth
- IVR N/A
- TCRX N/A
- EPS
- IVR N/A
- TCRX N/A
- Revenue
- IVR N/A
- TCRX $12,200,000.00
- Revenue This Year
- IVR N/A
- TCRX N/A
- Revenue Next Year
- IVR N/A
- TCRX $3.10
- P/E Ratio
- IVR N/A
- TCRX N/A
- Revenue Growth
- IVR N/A
- TCRX N/A
- 52 Week Low
- IVR $6.34
- TCRX $2.86
- 52 Week High
- IVR $9.97
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- IVR 47.31
- TCRX 43.56
- Support Level
- IVR $8.33
- TCRX $5.28
- Resistance Level
- IVR $8.53
- TCRX $5.68
- Average True Range (ATR)
- IVR 0.16
- TCRX 0.27
- MACD
- IVR -0.02
- TCRX 0.03
- Stochastic Oscillator
- IVR 37.61
- TCRX 56.25
About IVR INVESCO MORTGAGE CAPITAL INC
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.